Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodality Therapy with Trastuzumab for Breast Cancer
NCT00006110Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 1998
- Primary completion
- Mar 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab in breast cancer (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Cardiac Toxicity of Weekly Taxol Given With Weekly Herceptin at 78 weeks. Started Dec 1998; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00006110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006110.